The opioid epidemic has been called the "most consequential preventable public health problem in the United States." Though there is wide recognition of the role of prescription opioids in the epidemic, evidence has shown that heroin and synthetic opioids contribute to the majority of opioid overdose deaths. It is essential to reframe the preventive strategies in place against the opioid crisis with attention to factors surrounding the illicit use of fentanyl and heroin.
www.painphysicianjournal.com Source: Singer JA. Stop calling it an opioid crisis -it's a heroin and fentanyl crisis. Cato Institute, January 9, 2018. https://www.cato.org/blog/stop-calling-it-opioid-crisis-its-heroin-fentanyl-crisis (14) .
Fig. 2. Total opioid prescriptions (in millions), 2013-2017.
Source: Xponent, IQVIA (23) Department of Health and Human Services (HHS) and various organizations, including the National Institutes of Health (NIH), Food and Drug Administration (FDA), and Drug Enforcement Administration (DEA) aim to fight the opioid epidemic with science and regulation. The U.S. Congress and state and local authorities have focused enormous resources on this issue (1, 2, 5, (7) (8) (9) (10) (11) (14) (15) (16) . However, with changing public opinion and enormous visibility, this concern stems from the magnitude of opioid-related deaths reached in 2016, when more than 11 million Americans misused prescription opioids and overall drug overdose deaths in 2016 contributed to over 64,000 deaths with 42,249 due to opioids -20,145 associated with synthetic opioids other than methadone, 15,446 from heroin, 14,427 from natural and semi-synthetic opioids or prescription opioids, and 3,314 from methadone. In comparison, in 2016, cocaine overdose caused 10,619 deaths and methamphetamine 7,663 deaths as shown in Fig. 1 (5, 11, (14) (15) (16) .
Data shows that illicit fentanyl contributed to almost 50% of the deaths in 2016, whereas overall prescription opioid deaths without fentanyl or heroin but including other illicit drugs may have contributed to less than 8,000 in 2016 with methadone contributing to 3,314 deaths despite methadone prescriptions representing only 1% of total opioid prescriptions. In addition to the reduced production mandated by DEA (25% reduction in 2017, 20% in 2018) data shows a decline in total prescriptions and overall dosages, starting from 2013 with a reduction from 252 million opioid prescriptions in 2013 to 196 million in 2017 (annual decrease by 9%) as shown in Fig. 2 (15) (16) (17) (18) (19) (20) (21) (22) (23) . In fact, data from 2016-2017 showed a decrease by 23.3 billion in morphine milligram equivalents (MMEs) dispensed to patients on a volume basis, with a 12.2% decrease in prescriptions, and a 16.1% decline in patients receiving high doses (> 90 MMEs per day) as shown in Fig. 4 . It is 
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Reframing the Prevention Strategies of the Opioid Crisis postulated that further declines will occur throughout 2018. However, the decline in opioid prescription rate is not accompanied by a correlating decline in opioid abuse and death rate (Figs. 3 and 4) (23) .
In an analysis of deaths and years of life lost with percentage change, from the 25 leading causes of death in the United States from 1990-2016, opioid use disorders ranked 52 in 1990, moved up to 15 in 2010, and remained at 15 in 2016 (24, 25) . However, in terms of years lived with disability (YLDs), opioid use disorders ranked 7 in 1990 and 2010 and moved down to 8 in 2016, showing very little improvement over the years (24, 25) . It is now known that many deaths due to illicit fentanyl and heroin have been counted as prescription opioid deaths because of the inability to separate fentanyl formulation and metabolites of heroin (22) . In addition, fentanyl deaths increased 520% from 2009 to 2016 at an annual rate of 87.7% from 2013 to 2016, whereas heroin deaths increased 533% from 2000 to 2016 (14) (15) (16) . In fact, from 2015 to 2016, deaths attrib-www.painphysicianjournal.com The authorities and the public at large have appropriately focused on the opioid epidemic throughout its early years. Authors of this manuscript have argued strenuously for such consideration for some time (26) (27) (28) . It is essential to move the discussion forward by examining the more nuanced culprits of fentanyl and heroin. This article thus focuses on reframing the opioid epidemic as a prescription opioid fentanyl and heroin epidemic with the need to establish effective strategies.
Public Opinion
Blendon and Benson (11) , in a survey of public opinion on opioid-abuse epidemic, found that on a list of 15 possible 2017 priorities for Congress and the president, opioids ranked sixth, with 24% naming opioids an extremely important priority. The results of this survey also revealed that addiction to prescription pain medications was believed to be an illness by 53% and a personal weakness by 36% of surveyed patients. Further, public opinion on responsibility for the opioid crisis has been highly variable as evidenced by multiple surveys as shown in Table 1 and Fig. 6 (11,29,30 ). The results demonstrated that overall responsibility attributed to drug users varied from 10-29%, physicians 19-33%, drug companies 13-38%, and drug dealers 11-28%. In summary, it appears that in one survey, drug companies and distributors were considered the most responsible entities for the opioid crisis by 43% (30) followed by physicians in another survey by 33% (11), followed by 29% for drug users (29) and 28% for drug dealers (11) .
Evolution of thE opioid EpidEmic
Opioids date back 5,000 years from the use of extracts of the poppy plant, named the "joy plant" for medicinal purposes (31). Numerous over-the-counter medicinal products from 1849 have used morphine, opium, heroin, and cocaine including a sleep aide and analgesic for children that contained 65 mg of morphine sulfate per ounce as shown in Table 2 (31). An alcohol-based tincture of 10% powdered opium called "laudanum", was widely used leading to the addiction of many in the United States (31). "Soldier's disease", an epidemic of addiction during the Civil War, was caused by morphine, isolated from opium about 50 years earlier (31,32). Ironically, Bayer Pharmaceuticals marketed heroin as an analgesic and claimed it was less addictive than other opioids, as early as 1874. There were similar claims about multiple other opioids as well as cocaine. Sadly, there were an estimated 200,000 heroin addicts in the United States by 1972 (31). The federal legislation starting with the Heroin Act (1906) (1907) (1908) (1909) (1910) (1911) (1912) (1913) (1914) (1915) (1916) (1917) (1918) (1919) (1920) (1921) (1922) (1923) (1924) , which outlawed production and possession of heroin, was a response to control escalating toll of drug abuse (31). The Controlled Substance Act (CSA) was established in 1970. The CSA regulated narcotic manufacturing and distribution and classified controlled substances into five narcotic schedules (33) . By 1971, 15% of the soldiers in Vietnam had become heroin addicts. This led President Nixon to declare heroin "Public Enemy Number One" in 1972 and direct federal support toward the establishment of methadone clinics (34). However, methadone soon became a drug of abuse. Near the end of the century, the emergence of a new pain movement focused on under-treatment, the influence of the pharmaceutical industry, and the liberalization of multiple existing narcotics regulations contributed to the ensuing escalation in prescription opioid use, abuse, and overdose-related deaths (26, 27) .
Reframing the Prevention Strategies of the Opioid Crisis 
tragic failurE of SyStEmS
Despite overwhelming evidence that the epidemic of opioid use involves the use of prescription opioids, fentanyl, and heroin, policy experts appear to have focused on prescription opioids as the main target in the U.S. (1, (3) (4) (5) 14, (26) (27) 31) . In this regard, despite overwhelming evidence of misinformation and misdeeds by drug manufacturers, drug dealers, drug distributors, and multiple agencies overseeing controlled substance activities, policymakers have targeted over-prescription by physicians to a disproportionate extent. Along with illicit fentanyl and heroin, prescription opioids continue to contribute to deaths, but at a significantly lower rate.
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The confluence of the emergence of the influence of pharma and the death of evidence-based medicine originated with the Sackler brothers (31-35). The Sackler brothers, three psychiatrists, purchased Purdue Frederick Pharma in 1952 with an initial focus on laxatives and earwax. The company shifted its focus to pain management and released MS Contin in 1984. Subsequently, in 1996, OxyContin was released. Dr. Arthur Sackler, who died in 1987, had become a wealthy pharmaceutical marketing executive, publisher of medical trade publications, and father of direct to physician marketing (31, [35] [36] [37] . Arthur Sackler started MD Publications in the 1960s and promoted diazepam and chlordiazepoxide (Librium®), which led to over 100 million prescriptions per year by 1973. He infamously paid $300,000.00 to recruit Henry Welch, MD from the FDA to promote MD Publications.
OxyContin was falsely marketed as an opioid with low addiction potential based on a 1980 New England Journal of Medicine letter to the editor that claimed that under 1% of patients discharged on narcotics from the author's hospital developed addiction (38) . Lavish trips and stipends for marketing influenced physicians to prescribe OxyContin. In addition, Purdue Pharmaceutical employed a large aggressive sales force, offered a free 30-day supply of OxyContin, and promoted the theory of pseudo-addiction suggesting that more medication is required as patients hurt more (35) (36) (37) (38) . With the support of multiple pain organizations, the Joint Commission on Accreditation of Healthcare Organizations (JCAHO), the Veterans Health Administration (VHA), and other proactive groups, prescription of OxyContin and other opioids exploded (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) .
The Pain Movement with Confluence of Interest
Houde, Foley, and Portenoy led the way for opioid explosion through their academic stature and leadership positions in the American Pain Society (APS) (31, 39,53). Portenoy and Foley advocated that opioid maintenance therapy for chronic non-cancer pain was safe and humane based on a report of 38 cases (39) . The APS held the mantle as the advocacy group for opioid treatment of pain. It received much of its support from Purdue Pharma. It also promoted opioids as a management option in chronic low back pain publications (54) . The APS advocated the establishment of pain as the "fifth vital sign" in 1995. The APS and American Academy of Pain Medicine (AAPM) published a consensus statement in 1997 declaring evidence of addiction due to the appropriate prescription of opioids insufficient (41) . In 2010, the International Association for the Study of Pain (IASP) contributed a patients' rights component to the ongoing pain movement declaring patient's entitlement to access pain management treatments, including opioids (41) . The Veterans Affairs (VA) medical system, the Joint Commission (JCAHO), the American Medical Association (AMA), the American Academy of Family Physicians (AAFP), a number of pain organizations funded by Purdue Pharma, and many patient advocacy groups gathered in support of pain as the fifth vital sign (42) (43) (44) (45) . The fifth vital sign was eventually withdrawn in 2016 after its contributions to the opioid epidemic were recognized (43, 45) . JCAHO continues to establish new measures that are similar to pain as the fifth vital sign. In addition, multiple organizations advocating opioids for pain management successfully lobbied the US Congress to declare a decade of pain control and research in 2000 (41) . Another crucial event was the official implementation of pharma-developed opioid prescription policies in 2002 through the University of Wisconsin, Madison Pain Policy Study Group (PPSG), which received $2.5 million in grants from the industry with Purdue Pharma alone contributing $1.6 million (31,46). The Federation of State Medical Boards (FSMB) adapted the PPSG 2002 policies to produce a document entitled "Update and clarify state medical board policies on the use of opioid analgesics to treat pain" sent to medical licensure boards (47) . This report and policy model essentially unleashed opioid prescription patterns to ensure that physicians could not be sanctioned based on the dose or frequency of opioids prescribed for legitimate medical purposes as defined in the liberated 1970 Narcotics Control Act. This report has since become a cornerstone (no dose threshold) of pill mills during the explosion of the prescription opioid epidemic. Purdue Pharma provided $100,000 for the printing of 300,000 widely distributed copies of the FSMB model guidelines, which had been based on a single observational study by Portenoy in addition to expert opinions (39, 40) . The guidelines were developed not only with extensive bias and conflicts of interest but also in the absence of high-quality scientific studies (48) . Figure 7 shows organizational contributions made by opioid manufacturers from 2012 to March 2017 (55) . Earlier contributions were published in 2012 (56) .
draStic failurES in ovErSight
Over the years, drastic failures have occurred in oversight of not only opioid manufacturing, distribution, diversion, and import but also the medical (55) www.painphysicianjournal.com necessity and appropriate monitoring of opioid prescriptions. The Controlled Substance Act (CSA) of 1970 (33) essentially relaxed the anti-opioid portions of the Harrison Narcotics Tax Act of 1914 by outlining a legitimate medical purpose for opioids (33) : this would lead the path towards later oversight failures. The CSA also established the US Drug Enforcement Agency to set production quotas and to monitor and control diversion and excessive production of narcotics (50). The DEA was founded as an agency of the Department of Justice in July 1973 with the mission to combat drug smuggling and use within the United States. Without foreseeing the subsequent and obviously unintended consequences, the DEA joined 21 health care organizations in 2001 to call for improved approaches to assure that prescription opioids were available for medical use and shielded from diversion (51) . During this time, the provider community held a multitude of negative opinions of the DEA, and ASIPP was introducing its first version of the National All Schedules Prescription Electronic Reporting Act (NASPER) (52) .
Between 1996 and 2007, the DEA increased US production of opioids by 10-fold for fentanyl, 4-fold for hydrocodone, and 4.5-fold for hydromorphone. By 2007, it had just begun to establish quotas for OxyContin. Despite the extensive criticism it received for laxity on opioid prescribing regulation, the DEA sanctioned less than 0.1% of physicians for opioid prescribing violations from 1999 to 2003 (51, 53) .
In 2016, President Obama signed into law the Ensuring Patient Access and Effective Drug Enforcement Act, also known as the Marino Act. The act was described as "the crowning achievement of a multifaceted campaign of the drug industry to weaken the DEA enforcement activities against drug distribution companies that were supplying corrupt physicians and pharmacies who pedal narcotics on the black market" (57) . The Marino Act led to the closure of the DEA's Special Operations Unit, which faced congressional criticism after the unit was found to have covertly collected internal phone records to monitor drug traffic (57, 58) .
The FDA also made substantial unintentional contributions to the opioid epidemic. The FDA approval of OxyContin in 1995 is considered to have played a key role in one of the greatest medical disasters in U.S. history (31, 35, 36, 59) . In 1995, Dr. Curtis Wright, team medical review officer for the FDA, recommended approval of Purdue Pharma's OxyContin for moderate to severe pain. In an October 16, 1995 report for the FDA, Dr. Wright wrote the following: "…care should be taken to limit competitive production [of OxyContin]," two years before he began working for Purdue Pharma.
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Dr. David Kessler, FDA commissioner at the time OxyContin was approved, acknowledged, "no doubt it was a mistake. It was certainly one of the worst medical mistakes, a major mistake." It was also reported that a Purdue Pharma promotional video featuring success stories of patients treated for chronic pain with OxyContin included several patients who later died or became addicted to the drug (56) .
The FDA approved Opana® (oxymorphone) in 2006 despite a past history of oxymorphone abuse in the 1960s and 1970s resulting in the drug's removal from the market (56) . In 1995, the FDA approved tramadol as a non-controlled analgesic despite prior research indicating the drug's potential to be abused when it first arrived on the U.S. market (60) . The FDA also approved Zohydro (a hydrocodone product) on October 25, 2013, against the recommendation of the FDA's own appointed scientific advisory panel, which voted 11 to 12 against the approval (61) . Further, the approval of Zohydro was supported by FDA commissioner Margaret Hamburg, who cited the Institute of Medicine's statistics on chronic pain, including which were exaggerated and misleading (61). Hamburg spoke of "100 million Americans suffering from severe chronic pain," which became a central part of the debate used to justify Zohydro's approval (61) (62) (63) .
Among the multiple oversight agencies, boards of medical licensures governed by each state legislature, but also following unofficial mandate from Federation, have fueled the opioid epidemic with misinformation to physicians (46, 47) .
Industry
In comparison to prior drug industry contributions made to influence guidelines and promote products (31,46,55-57), recent publications from the Senate show similar patterns, with $9 million funneled to the leading pain treatment advocacy organizations and industry groups (Fig. 7) , that allegedly shaped policy and public opinion around opioids. Charitable funding from the Sackler family for numerous organizations and educational institutions has also recently come under attack (35, 36) . In fact, Marissa Sackler, daughter of Raymond Sackler, commented, "philanthropy is old fashioned -it is social entrepreneurship." The Ensuring Patient Access and Effective Drug Enforcement Act (HR-4709), often referred to as the Marino Act, received lobbying expenses of over $100 million from pharmaceutical companies over 2014-2016 (57). The Marino Act made it virtually impossible for the DEA to freeze suspicious narcotic shipments from distributors (57-59). Joseph Rannazzisi, former head of the DEA's Office of Diversion Control notably influential in closing pill mills in multiple Florida jurisdictions, commented, "The drug industry, the manufacturers, wholesalers, distributors, and chain drugstores have an influence over Congress that has never been seen before," regarding the Marino Act. John J. Mulrooney II, DEA Chief Administrative Law Judge, commented, "At a time when by all accounts, opioid abuse, addiction, and deaths were increasing markedly," the Marino Act "imposed a dramatic diminution of the agency's authority (57) ."
thE truE EpidEmic
OxyContin was reformulated to become more difficult to abuse in 2010. Ostensibly, reformulation reduced non-medical use and abuse, but a spike in heroin users followed (35, 36, (64) (65) (66) . Mexico is the largest source of heroin used in the United States. The increasing demand for heroin in the early 1970s resulted in the emergence of a new breed of Mexican drug cartels producing "black tar heroin" (31) (Fig. 8) . Coupled with the increase in heroin abuse was the introduction of fentanyl, an opioid 80 times more potent than heroin first marketed in the United States as Duragesic in the 1990s (67) . Drug dealers began adding fentanyl to heroin for a more potent effect. Of note, in 2016, fentanyl was involved in half of all overdose deaths in Illinois (68). United States drug companies took measures to curtail fentanyl overproduction. Around this time, China began to produce large quantities of fentanyl and develop fentanyl derivatives sold to heroin producers in Mexico and drug users in the United States (31). In addition, carfentanil, an elephant tranquilizer 100 times more potent than fentanyl --essentially 8,000 times more potent than heroin --led to overdoses in Ohio, New York, Pennsylvania, Florida, and neighboring states (69, 70) . Table 3 outlines the many factors that contributed to the opioid crisis, throughout which multiple states have sued drug companies and reached large settlements and awards.
In recent years, prescription opioid usage has decreased with the development of a multitude of federal, state, and local regulations. Regulations limiting opioid prescriptions for acute pain to 3-to-10 days courses have somewhat reduced the supply of prescription opioids available for non-medical use. CDC guidelines have included dose recommendations for prescribing opioids in primary care. In many jurisdictions, these guidelines have become regulations across specialties, including chronic pain management. The combined prescription of opioids and benzodiazepines has also declined following an FDA black box warning in 2016 (70).
diScordancE: curbing thE EpidEmic or dEnying thE trEatmEnt?
Here, we present divergent views on the opioid epidemic and the rise of heroin in conjunction with fentanyl.
According to Andrew Kolodny, founder of Physicians for Responsible Opioid Prescribing (PROP), most opioid overdose deaths had involved prescription opioids until 2011. Then, as prescription overdose deaths leveled off, deaths involving heroin began to soar. Kolodny considers the belief that a 2011 federal government crackdown on painkillers was responsible for many prescription drug abusers' switch to heroin a common misconception. Though a slowdown in opioid prescription may have occurred around 2011, oxycodone consumption has remained higher on a milligram per capita scale in the United States than in other developed countries, as shown in Figure 9 . Lack of physician discipline in avoiding over-prescription played a significant role, but it was ease of access that had already influenced the vast majority of people who'd started using heroin after 1995 to make the switch from prescription opioids. A sharp increase in overdose deaths occurred in 2011 in part because of the increasing illicit use of fentanyl, an inexpensive but potent synthetic opioid that was often mixed with or sold as heroin. Once medical examiners began to routinely test heroin overdose victims for the presence of fentanyl in 2013, an alarming trend in the identification of fentanyl as a cause of overdose deaths appeared. Data in 2016 indicated deaths from fentanyl reached 20,000, thus surpassing deaths from prescription opioids and heroin.
According to Josh Bloom of the American Council on Science and Health, nonmedical use of OxyContin started declining after the introduction of reformulated Oxycodone ER in 2010, pushing patients to heroin as shown in Fig. 10 . Figure 10B shows escalating deaths due to heroin overdose following 2010. Further, Fig. 11 compares national overdose deaths from prescription opioid pain relievers (Fig. 11A) , which stayed stable with slight increases as heroin deaths escalated as shown in Fig. 11B (66) . Figures 1 and 5 show the quantification of opioid death rates from 2001-2016. From 2001-2009, prescription opioid deaths increased by 159%, and deaths due to synthetic opioids other than methadone increased 233%. The rise in deaths from prescription opioids was slower from 2009 to 2016, over which prescription opioid deaths increased 18% overall at an annual rate of 3%. By contrast, from 2013 to 2016, synthetic opioids other than methadone increased 520% overall, 87.7% annually, fentanyl deaths topping in 2016 with over 20,000 deaths (71) (72) (73) (74) . Figures 12-14 show that alongside the rise in drugrelated deaths from 2009-2016 occurred a decrease in the utilization of multiple lumbar interventional techniques, including epidurals, percutaneous adhesiolysis, and lumbar facet joint nerve blocks. This decrease occurred despite the promotion of interventional pain procedures by multiple agencies and despite the availability of data from high quality randomized controlled trials that had undergone systematic reviews and costutility analysis .
rEframing thE prEvEntion StratEgiES
Over the past two decades, the American Society of Interventional Pain Physicians (ASIPP) has offered extensive pain management continuing education resources and received recognition by Congress and the Administration as a political action committee. ASIPP began issuing warnings and offering preventive measures in early 2000 with its proposal of a national program -the www.painphysicianjournal.com www.painphysicianjournal.com
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Reframing the Prevention Strategies of the Opioid Crisis A systematic review by Fink et al (111) assessed 17 studies, 13 on fatal overdoses and 4 on nonfatal overdoses. Three of the 4 nonfatal overdose studies offered insufficient evidence to suggest any conclusions on the effect of PDMP implementation on nonfatal overdoses. Three of the 4 nonfatal overdose studies offered insufficient evidence to characterize the effect of PDMP implementation on total nonfatal overdoses. Ten of the fatal overdose studies offered low-strength evidence that PDMP implementation reduced total fatal overdoses. The review examined 6 studies on the relationship between PDMP implementation and heroin overdose deaths. Three of the studies found that with PDMP implementation occurred an increase in heroin overdoses. The others found that with PDMP implementation, there was a non-statistically-significant decrease in heroin overdoses (111) .
To control the fentanyl and heroin epidemic, one must understand that the majority of the people who use heroin are not seeking fentanyl and essentially are trying to avoid it (71) . However, the technology of illicit drug production has advanced to the extent that consumers often cannot correctly identify the products they obtain. Fentanyl in white powder form is in particular difficult to differentiate from other products (72 (73) . Another study found an increase in the self-reported use of fentanyl -referred to as "unknown fentanyl products" -from 9% in 2014 to 15% in 2016 among the population entering drug treatment (n = 10,900) (74) . Consequently, the number of prescription opioid admissions has declined and illicit fentanyl and heroin admissions has increased.
ASIPP 3-Tier Approach to Curb Opioid Abuse
ASIPP aims to curb illicit fentanyl, heroin, and prescription drug abuse while maintaining appropriate access to and proper use of pain management modalities. Consequently, ASIPP has suggested more effective legislation to curb opioid abuse, reducing deaths, while promoting nonopioid modalities such as interventional techniques (26, (85) (86) (87) (88) (89) (90) (91) (92) (93) (94) (95) (96) (97) (98) (99) (100) (101) (102) (103) . Following is the ASIPP threetier approach toward achieving this goal.
Tier 1
1. Institute an aggressive public education campaign with explicit teaching on the dangers of using illicit drugs, specifically heroin and fentanyl. 2. Institute a public education campaign on opioid abuse in general with emphasis on the adverse consequences of the combined use of opioids and benzodiazepines.
• The diversity of public opinion, regarding which parties are most responsible for the opioid crisis, is illustrated in Table 1 and Fig.  7 (11,29,30 ). 3. Implement physician education that excludes the involvement of industry. Make mandatory at least four hours of continuing education per year for each prescriber of any amount of opioids or benzodiazepines. 4. Implement mandatory patient education upon the first prescription of any amount of opioid.
Tier 2
5. Reduce or eliminate copayments to make nonopioid pain management techniques, including physical therapy and interventional procedures, more accessible and improve patient pain and function outcomes (24, 113, 114) .
• Ironically, as both reimbursements for and utilization of interventional procedures have decreased since 2010, opioid deaths have escalated . The direct inverse relationship, between the performance of interventional pain procedures and the number of opioid deaths per year, is illustrated in figures 12-14. 6. Expand low-threshold access to buprenorphine for opioid use disorder (3, 5, 115) . It has been shown that a substantial proportion of patients who would benefit from buprenorphine treatment will receive this only if it becomes more attractive and more accessible than either prescription or illicit opioids (3).
• Opioid overdose deaths were shown to decrease by 79% over a period of 6 years after the initiation of widespread buprenorphine prescription in France (115) . Expanding low-threshold access will also pave the way toward making buprenorphine and its products available in the management of chronic pain (as described under tier 3). 7. Increase the capacity of each state's PDMP to interact at a minimum with all bordering state PDMPs through the NASPER Act. 8. Enforce mandated review of PDMP data prior to all opioid and benzodiazepine prescriptions.
Tier 3
9. Make buprenorphine available as an agent for chronic pain management as well as for medication-assisted treatment. We propose changing the controlled substance classification of buprenorphine from Schedule III to Schedule II to facilitate this. 10. Remove methadone, responsible for over 3,000 deaths per year while comprising only 1% of total opioid prescriptions, from formulary as a listed preferred drug.
concluSion
Americans are facing an opioid crisis of epidemic proportions. It is important to note the degree to which illicit fentanyl and heroin, as well as prescription opioids, contribute to this crisis. This manuscript has discussed numerous factors that have led to this current state -the public's perception of opioid use, the evolution of the opioid epidemic over the past three Reframing the Prevention Strategies of the Opioid Crisis centuries, the influence of greed-based advocacy on the pain movement, failures in the oversight of philanthropy, and the tragic failure of multiple systems that are in place to protect the public due to a confluence of greed. These factors have contributed to misinformation in the development of guidelines and have precipitated ineffective measures by federal, state, and local authorities, governing the use of opioids. Understanding the crisis is critical for providers and policymakers. We have proposed a 3 tier approach toward tackling this scourge.
